Literature DB >> 33359114

Recent advances in HER2-targeted delivery for cancer therapy.

Rakesh Kumar Dhritlahre1, Ankit Saneja2.   

Abstract

Human epidermal growth factor receptor 2 (HER2), a tyrosine kinase receptor with a molecular mass of 185kDa, is overexpressed in several cancers, such as breast, gastric, ovary, prostate, and lung. HER2 is a promising target in cancer therapy because of its crucial role in cell migration, proliferation, survival, angiogenesis, and metastasis through various intracellular signaling cascades. This receptor is an ideal target for the delivery of chemotherapeutic agents because of its accessibility to the extracellular domain. In this review, we highlight different HER2-targeting strategies and various approaches for HER2-targeted delivery systems to improve outcomes for cancer therapy.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33359114     DOI: 10.1016/j.drudis.2020.12.014

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

Review 1.  Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy.

Authors:  Masoom Raza; Naveen Kumar; Uttara Nair; Gehna Luthra; Ushosi Bhattacharyya; Smruthi Jayasundar; Rama Jayasundar; Seema Sehrawat
Journal:  Mol Cell Biochem       Date:  2021-04-22       Impact factor: 3.396

Review 2.  Chemical Conjugation in Drug Delivery Systems.

Authors:  Alexis Eras; Danna Castillo; Margarita Suárez; Nelson Santiago Vispo; Fernando Albericio; Hortensia Rodriguez
Journal:  Front Chem       Date:  2022-05-26       Impact factor: 5.545

3.  Improvement of cytotoxicity and necrosis activity of ganoderic acid a through the development of PMBN-A.Her2-GA as a targeted nano system.

Authors:  P Motamed Fath; M Rahimnejad; S Moradi-Kalbolandi; B Ebrahimi Hosseinzadeh; T Jamshidnejad-Tosaramandani
Journal:  RSC Adv       Date:  2022-01-05       Impact factor: 3.361

4.  Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.

Authors:  Long Chen; Fukun Chen; Huatao Niu; Jindan Li; Yongzhu Pu; Conghui Yang; Yue Wang; Rong Huang; Ke Li; Yujie Lei; Yunchao Huang
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.